Table 4 New therapeutic agents used for osteosarcoma by targeting osteoclasts and immune system based on the clinical trials (Niche cells and their signalling), data provided from https://clinicaltrials.gov
From: Novel molecular insights and new therapeutic strategies in osteosarcoma
Status | Conditions | Interventions | Phase | Last update posted |
|---|---|---|---|---|
Recruiting | Osteosarcoma | Drug: Avelumab (monoclonal antibody) | Phase 2 | June 25, 2018 |
Recruiting | Osteosarcoma | Drug: Pembrolizumab (IgG4 isotype antibody) | Phase 2 | April 5, 2018 |
Recruiting | Metastatic osteosarcoma | Drug: Sm-EDTMP Other: Autologous stem cell infusion Radiation: External beam radiotherapy | Phase 2 | February 14, 2018 |
Unknown | Osteosarcoma | Drug: Zoledronic acid (type of drug: bisphosphonates; target: Osteoclasts) Drug: Standard chemotherapy | Phase 2 Phase 3 | June 23, 2011 |
Active, not recruiting | Recurrent osteosarcoma | Drug: Glembatumumab Vedotin Antibody–drug conjugate Other: Laboratory biomarker analysis Other: Pharmacological study | Phase 2 | May 7, 2018 |
Completed | Osteosarcoma | Drug: Cisplatin Drug: Doxorubicin Drug: Methotrexate Administration of Pamidronate (drug type: bisphosphonates; target: osteoclasts) with chemotherapy | Phase 2 | January 20, 2016 |
Recruiting | Recurrent osteosarcoma | Biological: Humanized anti-GD2 antibody (drug type: monoclonal antibody; target: immune system) Drug: GM-CSF | Phase 2 | August 2, 2018 |
Active, not recruiting | Childhood osteosarcoma Metastatic osteosarcoma Recurrent osteosarcoma (and 3 more…) | Biological: Denosumab (drug type: monoclonal antibody; target: RANKL) | Phase 2 | August 7, 2018 |
Completed | Sarcoma | Zoledronic acid (type of drug: bisphosphonates; target: osteoclasts Drug: cisplatin Drug: Dexrazoxane hydrochloride Drug: doxorubicin hydrochloride (and 10 more…) | Phase 1 | July 4, 2014 |
Completed | Neuroblastoma Melanoma Osteosarcoma Ewing sarcoma | Biological: Anti-GD2 antibody (drug type: monoclonal antibody; target: immune system) | Phase 1 | Â |
Terminated | Sarcoma | Zoledronic acid (type of drug: bisphosphonates; target: osteoclasts Drug: Cisplatin Drug: Doxorubicin hydrochloride Drug: Etoposide (and 4 more…) | Phase 3 | June 22, 2016 |
Recruiting | Desmoplastic small round cell tumor Disseminated neuroblastoma Metastatic osteosarcoma (and 2 more…) | Biological: IL-2 Biological: GD2Bi-aATC (drug type: cells Biological: GM-CSF Evaluations of immune responses | Phase 1 Phase 2 | December 4, 2017 |
Completed | Osteosarcoma | Drug: c (type of target: Monocyte/macrophage activator glycopeptide) Drug: Ifosfamide | Phase 2 | March 22, 2017 |
Not yet recruiting | Bone sarcoma Soft tissue sarcoma | Biological: NY-ESO-1 (target: immunotherapy; TCR affinity enhancing specific T cell therapy) | Phase 2 | March 16, 2018 |
| Â | Ewing sarcoma Osteosarcoma Rhabdomyosarcoma | Biological: Expanded, activated NK cells | Phase 1 Phase 2 | November 6, 2017 |
Active, not recruiting | Soft tissue sarcoma Bone sarcoma | Drug: Pembrolizumab: MK-3475 (cancer immunotherapy: target: PD-1 ) | Phase 2 | July 25, 2018 |
Recruiting | Recurrent malignant solid neoplasm Recurrent osteosarcoma Refractory malignant solid neoplasm Refractory osteosarcoma | Biological: Anti-SEMA4D monoclonal antibody VX15/2503 | Phase 1 Phase 2 | August 9, 2018 |
Recruiting | Ewing sarcoma Osteosarcoma Rhabdomyosarcoma | Biological: Expanded, activated NK cells (target: Immune system) | Phase 1 Phase 2 | November 6, 2017 |
Completed | Sarcoma Osteosarcoma Neuroblastoma Melanoma | Biological: Anti-GD2-CAR engineered T cells Drug: AP1903 Drug: Cyclophosphamide | Phase 1 | July 6, 2018 |
Recruiting | Ewing sarcoma Neuroblastoma Rhabdomyosarcoma (and 2 more…) | Procedure: Allogeneic HCT Drug: Donor NK Cell Infusion (target: immune system) | Phase 2 | June 1, 2018 |
Active, not recruiting | Neuroblastoma Ewing sarcoma Rhabdomyosarcoma (and 2 more…) | Procedure: haploidentical stem cell transplantation and NK cell therapy (target: Immune system) | Phase 2 | October 18, 2016 |
Recruiting | Neuroblastoma Rhabdomyosarcoma Osteosarcoma (and 3 more…) | Drug: Enoblituzumab (monoclonal antibody) | Phase 1 | August 7, 2018 |
Not yet recruiting | Soft tissue sarcoma Bone sarcoma Chondrosarcoma (and 5 more…) | Drug: Ipilimumab (Drug type: monoclonal antibody; target: CTLA-4 receptor) Drug: Nivolumab (IgG4 anti-PD-1 monoclonal antibody; target: PD-1 | Phase 2 | November 1, 2017 |